Second Birmingham Gynaecological Cancer Workshop on Second Line Treatment of Ovarian Cancer
Author Information
Author(s): G. Blackledge, C.W.E. Redman
Hypothesis
What factors influence the response to second line treatment in ovarian cancer?
Conclusion
The workshop highlighted the challenges in improving outcomes for women with advanced ovarian cancer and emphasized the need for careful patient selection in clinical trials.
Supporting Evidence
- 92 patients were analyzed to identify predictive factors for chemotherapy response.
- Three independent predictive variables were identified: interval from prior therapy, FIGO stage, and residual disease size.
- The classification function predicted outcomes correctly in 88% of patients.
Takeaway
Doctors are trying to find better ways to help women with ovarian cancer when their first treatment doesn't work, but it's really hard to know which medicine will help each person.
Methodology
Retrospective analysis of patients treated in phase II studies over three years.
Potential Biases
Potential bias in patient selection for trials may mask the benefits of second-line therapies.
Limitations
The variability in response rates and the difficulty in evaluating new treatments due to patient selection.
Participant Demographics
Patients treated by the West Midlands Ovarian Cancer Group, primarily those relapsing after primary treatment.
Want to read the original?
Access the complete publication on the publisher's website